2020 CANCER DIAGNOSTICS INNOVATION WORKSHOP
(FOCUS ON NEAR-PATIENT USE)

October 8-9, 2020 | Virtual Meeting via WebEx

Website: https://events.cancer.gov/cd2/innovation-ws

AGENDA

DAY 1: October 8, 2020

9:30 am – 10:00 am Join the Meeting / Computer Check
10:00 am – 10:15 am Welcoming Remarks and Meeting Overview/Charge for the Day
   Douglas R. Lowy, MD, Principal Deputy Director, NCI
   Christopher Hartshorn, PhD, Program Director, Division of Cancer Treatment and Diagnosis, NCI

SESSION I: STATE OF THE SCIENCE – CERVICAL CANCER
Screening for geographically isolated, medically underserved, and otherwise vulnerable communities

10:15 am – 10:20 am Session Introduction
   Chair: Vikrant Sahasrabuddhe, MBBS, DrPH, Program Director, Division of Cancer Prevention, NCI

10:20 am – 10:40 am Public Health Burden of Cervical Cancer and Emerging Trends of its Etiology
   Mona Saraiya, MD, MPH, Medical Epidemiologist, NCI and CDC

10:40 am – 10:50 am Break

10:50 am – 11:10 am Barriers and Facilitators to Patient Care
   Jacqueline Miller, MD, FACS, CAPT, US Public Health Service, Medical Director, National Breast and Cervical Cancer Early Detection Program, CDC

11:10 am – 11:30 am Currently Available Diagnostics
   Mark Schiffman, MD, MPH, Senior Investigator, Division of Cancer Epidemiology and Genetics, NCI

11:30 am – 11:40 am Break

11:40 am – 12:00 pm Community-based Strategies for the Use of Cancer Diagnostic Devices in Populations Experiencing Health Disparities and Health Inequities
   Erin Kobetz, PhD, MPH, Associate Director, Population Science and Cancer Disparity, University of Miami

12:00 pm – 12:20 pm Considerations from Bench to Bedside to Community
   Philip Castle, PhD, MPH, Director, Division of Cancer Prevention, NCI

12:20 pm – 12:30 pm Q&A

12:30 pm – 1:30 pm Lunch Break

SESSION II: REMARKS FROM SENIOR LEADERSHIP

1:30 pm – 2:00 pm
   Norman E. Sharpless, MD, Director, NCI
   Anand Shah, MD, Deputy Commissioner for Medical and Scientific Affairs, FDA

SESSION III: STATE OF THE SCIENCE - BLADDER CANCER
Cancer surveillance

This agenda is subject to change. (Draft as of 09.23.2020)
2:00 pm – 2:05 pm  
Session Introduction  
Chair: George Netto, MD, Chair of Pathology, University of Alabama at Birmingham

2:05 pm – 2:25 pm  
Clinical Course in Bladder Cancer and Clinical Needs for Near-patient Testing  
Charles Rosser, MD, MBA, FACS, Medical Director, Cancer Clinical Trials Office, Cedars-Sinai

2:25 pm – 2:45 pm  
Current Clinical and Emerging Markers of Bladder Cancer for Monitoring of Recurrence  
David McConkey, PhD, Director, Johns Hopkins Greenberg Bladder Cancer Institute

2:45 pm – 3:00 pm  
Q&A

3:00 pm – 3:10 pm  
Break

SESSION IV: STATE OF THE SCIENCE – LIVER CANCER
Screening in high risk patient populations

3:10 pm – 3:15 pm  
Session Introduction  
Chair: Fasiha Kanwal, MD, MSHS, AGAF, Chief, Section of Gastroenterology and Hepatology, Baylor College of Medicine

3:15 pm – 3:35 pm  
Current Clinical and Emerging Markers for Liver Disease to Guide Patient Stratification and Risk  
Rohit Loomba, MD, Professor of Medicine, University of California San Diego

3:35 pm – 3:55 pm  
Needs for Bringing Liver Disease Screening Platforms Out of Hospital and to Patients  
Xin Wei Wang, PhD, Deputy Chief, Center for Cancer Research, NCI

3:55 pm – 4:05 pm  
Break

4:05 pm – 4:25 pm  
Current Diagnostic Strategies for Hepatocellular Carcinoma and Emerging Near-patient Earlier Detection Platforms  
Shan Wang, PhD, Professor, Stanford University

4:25 pm – 4:40 pm  
Q&A

4:40 pm – 4:50 pm  
Wrap-up / Closing Remarks  
Robin Vanderpool, DrPH, Branch Chief, Division of Cancer Control and Population Sciences, NCI
DAY 2: October 9, 2020

9:30 am – 10:00 am  Join the Meeting / Computer Check

10:00 am – 10:10 am  Welcoming Remarks and Charge for the Day  
Ashim Subedee, PhD, Academic Innovation Lead, Small Business Education and Entrepreneurial Development, NIH OER  
Živana Težak, PhD, Associate Director, Center for Devices and Radiological Health, FDA

SESSION I: EMERGING FIELD  
Liquid biopsy

10:10 am – 10:15 am  Session Introduction  
Chair: Geoffrey Oxnard, MD, Medical Oncologist, Foundation Medicine Inc.

10:15 am – 10:35 am  Pathways to Bringing Emerging Liquid Biopsy Technologies for Cancer Screening and Near Patient Testing  
Nickolas Papadopoulos, PhD, Professor of Oncology, Johns Hopkins University School of Medicine

10:35 am – 10:55 am  Implementation needs in cancer screening and surveillance for bringing liquid biopsy technologies to more patient populations  
Catherine Marinac, PhD, Member of Faculty, Dana-Farber Cancer Institute

10:55 am – 11:05 am  Q&A

11:05 am – 11:15 am  Break

SESSION II: CASE STUDIES

11:15 am – 11:40 am  Overview of the Different Types of Near Patient Diagnostics, Approvals, and Expectations  
Chair: Marina Kondratovich, PhD, Associate Director, Center for Devices and Radiological Health, FDA

11:40 am – 12:00 pm  The OncoE6™ Cervical Test: Updates on the Technology and on Current and Future Avenues of Its Implementation  
Johannes Schweizer, PhD, Chief Science Officer, Arbor Vita

12:00 pm – 12:10 pm  Break

12:10 pm – 12:30 pm  Cologuard Colon Cancer Screening Test (FDA approved)  
Graham Lidgard, PhD, Chief Science Officer, Exact Sciences Corporation

12:30 pm – 12:40 pm  Q&A

12:40 pm – 1:30 pm  Lunch Break

SESSION III: WORLD CAFÉ BREAKOUT GROUPS

1:30 pm – 1:50 pm  Remarks from Senior Leadership and Introduction to the World Café Process  
Diana Espinosa, MPP, Deputy Administrator, HRSA  
Shari M. Ling, MD, Deputy Chief Medical Officer, CMS  
Sonia Rosenfield, PhD, Health Science Administrator, Center for Research Strategy, NCI

1:50 pm – 2:00 pm  Room Transition / Break

2:00 pm – 2:30 pm  World Café Session #1

2:30 pm – 2:40 pm  Room Transition / Break

2:40 pm – 3:00 pm  World Café Session #2

This agenda is subject to change. (Draft as of 09.23.2020)
3:00 pm – 3:10 pm  
**Room Transition / Break**

3:10 pm – 3:30 pm  
**World Café Session #3**

3:30 pm – 3:50 pm  
**Room Transition / Break**

3:50 pm – 4:25 pm  
**World Café, Reporting Out**  
Anand Pathak, PhD, MD, MPH, Medical Officer, Center for Devices and Radiological Health, FDA  
LeeAnn Bailey, PhD, Branch Chief, Center to Reduce Cancer Health Disparities, NCI  
Sabrina Matoff-Stepp, PhD, Senior Advisor, Office of Planning, Analysis, and Evaluation, HRSA

4:25 pm – 4:35 pm  
**Next Steps and Closing Remarks**  
Henry Rodriguez, PhD, MBA, Director, Office of Cancer Clinical Proteomics Research, NCI

---

**World Café Breakout Questions:**

- **Question #1: Barriers and Challenges Theme** - What are major barriers and challenges to bringing cancer diagnostics for near patient use in geographically isolated, medically underserved, and otherwise vulnerable communities?  
  **Facilitator:** Anand Pathak, PhD, MD, MPH, Medical Officer, Center for Devices and Radiological Health, FDA  
  **Notetakers:** Tara Hiltke, PhD, Program Director, Office of Cancer Clinical Proteomics Research, NCI and Camella Rising, PhD, MS, RDN, Cancer Research Training Award Fellow, NCI

- **Question #2: Opportunities and Action Items Theme** - What are the opportunities (i.e. facilitators, resources) to streamline / accelerate cancer diagnostics from design to implementation in these communities?  
  **Facilitator:** LeeAnn Bailey, PhD, Branch Chief, Center to Reduce Cancer Health Disparities, NCI  
  **Notetakers:** Rao Divi, Program Director, Division of Cancer Control and Population Sciences, NCI and Peter Delnero, PhD, MPH, Cancer Prevention Fellow, NCI

- **Question #3: Progress through Collaboration Theme** - How can the Federal partners support, incentivize and promote cancer diagnostics developers?  
  **Facilitator:** Sabrina Matoff-Stepp, PhD, Senior Advisor, Office of Planning, Analysis, and Evaluation, HRSA  
  **Notetakers:** Tiffany Gillis-Brown, JD, Public Health Analyst, HRSA and Mark Lowry, PhD, MA, Cancer Research Training Award Fellow, NCI